2022 Annual Shareholders’ Meeting Results

Stock Exchange Announcement STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) 2022 Annual Shareholders' Meeting Results Auckland, New Zealand, 24 August 2022 - Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company's annual shareholders' meeting held today were passed. The 11 resolutions were: Resolution 1: To re-elect Lewis Gradon as a director. Resolution 2: To re-elect Neville Mitchell as a director. Resolution 3: To re-elect Donal O'Dwyer as a director. Resolution 4: To elect Lisa McIntyre as a director. Resolution 5: To elect Cather Simpson as a director. Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor. Resolution 7: To approve the issue of performance share rights to Lewis Gradon. Resolution 8: To approve the issue of options to Lewis Gradon. Resolution 9: To approve the North America 2022 Employee Stock Purchase Plan. Resolution 10: To approve the 2022 Performance Share Rights Plan - North America. Resolution 11: To approve the 2022 Performance Share Option Plan - North America. All resolutions were decided by poll. The details of the total number of votes cast online, via phone or by proxy on the polls were as follows: Resolution Votes Resolution 1: To re-elect Lewis Gradon as a director For: 417,970,319 (99.99%); Against: 30,222; Abstain: 83,434; Total: 418,083,975 Resolution 2: To re-elect Neville Mitchell as a director For: 411,128,146 (98.36%); Against: 6,860,053; Abstain: 95,776; Total: 418,083,975 Resolution 3: To re-elect Donal O'Dwyer as a director For: 410,700,203 (98.28%); Against: 7,177,829; Abstain: 205,943; Total: 418,083,975 Resolution 4: To elect Lisa McIntyre as a director For: 417,824,318 (99.99%); Against: 56,047; Abstain: 203,610; Total: 418,083,975 Resolution 5: To elect Cather Simpson as a director For: 417,779,788 (99.97%); Against: 105,828; Abstain: 198,359; Total: 418,083,975 Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor For: 412,820,609 (99.30%); Against: 2,902,593; Abstain: 2,360,773; Total: 418,083,975 Resolution 7: To approve the issue of performance share rights to Lewis Gradon For: 406,452,228 (97.42%); Against: 10,773,351; Abstain: 294,521; Total: 417,520,100 Resolution 8: To approve the issue of options to Lewis Gradon For: 406,325,338 (97.39%); Against: 10,895,306; Abstain: 299,376; Total: 417,520,020 Resolution 9: To approve the 2022 Employee Stock Purchase Plan For: 416,172,287 (99.59%); Against: 1,715,840; Abstain: 195,848; Total: 418,083,975 Resolution 10: To approve the 2022 Performance Share Rights Plan - North America For: 415,456,483 (99.44%); Against: 2,358,647; Abstain: 267,250; Total:418,082,380 Resolution 11: To approve the 2022 Performance Share Option Plan - North America For: 416,914,483 (99.81%); Against: 813,161; Abstain: 354,656; Total: 418,082,300 About Fisher & Paykel Healthcare Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com. Media & Investor Contacts: Karen Knott GM Corporate Communications karen.knott@fphcare.co.nz +64 21 713 911 Hayden Brown Investor Relations Manager hayden.brown@fphcare.co.nz +64 27 807 8073 Authorised by Raelene Leonard, General Counsel & Company Secretary. End CA:00397563 For:FPH Type:MEETING Time:2022-08-24 16:36:49